HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo

Combinations of proteasome inhibitors and histone deacetylases (HDAC) inhibitors appear to be the most potent to produce synergistic cytotoxicity in preclinical trials. We have recently confirmed that L-carnitine (LC) is an endogenous HDAC inhibitor. In the current study, the anti-tumor effect of LC...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Huang, Hongbiao, Liu, Ningning, Yang, Changshan, Liao, Siyan, Guo, Haiping, Zhao, Kai, Li, Xiaofen, Liu, Shouting, Guan, Lixia, Liu, Chunjiao, Xu, Li, Zhang, Change, Song, Wenbin, Li, Bing, Tang, Ping, Dou, Q. Ping, Liu, Jinbao
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Public Library of Science 2012
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3527572/
https://ncbi.nlm.nih.gov/pubmed/23285100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0052576
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items